Hypothesis

Age-related decline in α‑ketoglutarate (AKG) causes succinate accumulation, which inhibits prolyl hydroxylase domain (PHD) enzymes and stabilizes HIF‑1α, driving a pseudohypoxic state that contributes to inflammation and aberrant DNA methylation. Supplementation with AKG reverses this by restoring the AKG/succinate ratio, reactivating PHD‑mediated HIF‑1α hydroxylation and degradation, thereby reducing HIF‑1α‑dependent transcriptional programs and allowing normal TET‑mediated demethylation to proceed. This positions AKG’s anti‑aging effect as a metabolic repair of TCA cycle flux rather than a hormetic stress response or a direct TET cofactor effect alone.

Mechanistic Rationale

• AKG is a competitive inhibitor of succinate at the PHD active site; high succinate/low AKG ratios impair HIF‑1α hydroxylation, leading to its stabilization even under normoxia [1].
• Aging is associated with a ~10‑fold drop in plasma AKG [1], while succinate rises with mitochondrial dysfunction, creating conditions for HIF‑1α accumulation.
• Stabilized HIF‑1α recruits histone deacetylases and DNA methyltransferases to hypoxia‑responsive elements, promoting hypermethylation at specific CpG sites and suppressing TET access [2]
• Restoring AKG lowers succinate, reactivates PHDs, decreases HIF‑1α protein, and reduces HIF‑1α‑driven epigenetic noise, permitting TET enzymes to demethylate targets that were previously blocked.
• The observation that AKG supplementation yields both demethylation and hypermethylation at distinct CpGs [3] fits a model where normalized HIF‑1α signaling reshapes the epigenetic landscape rather than globally saturating TET activity.
• Lack of correlation between treatment duration (4‑10 months) and effect size [3] supports a threshold model: once the AKG/succinate ratio is corrected, further AKG confers no additional benefit, inconsistent with a classic hormetic dose‑response.

Testable Predictions

1. In aged wild‑type mice, 1 g kg⁻¹ day⁻¹ calcium‑AKG for 8 weeks will reduce hepatic and muscular HIF‑1α protein levels by ≥30 % compared with vehicle, measured by western blot and ELISA.
2. The HIF‑1α reduction will be abolished in mice with liver‑specific PHD2 knockdown or expressing a PHD2 mutant that cannot bind AKG, confirming AKG’s action via PHDs.
3. In TET2/3 double‑conditional knockout mice, AKG will still lower HIF‑1α protein but will fail to produce the demethylation of HIF‑1α target promoters seen in wild‑type animals, indicating that HIF‑1α regulation is upstream of TET activity.
4. Downstream HIF‑1α targets (e.g., Vegfa, Glut1, Il1b) will show decreased mRNA and protein levels, correlating with reduced serum IL‑6 and TNF‑α.
5. If AKG’s benefits are purely hormetic, then intermittent dosing (e.g., 3 days on/4 days off) should maintain or enhance HIF‑1α suppression; our model predicts no added benefit beyond continuous dosing that restores the metabolite ratio.

Falsification Criteria

• If AKG supplementation does not decrease HIF‑1α protein in aged wild‑type tissue, or if HIF‑1α reduction occurs equally in PHD2‑deficient contexts, the proposed mechanism is refuted.
• If HIF‑1α lowering persists without any change in the AKG/succinate ratio (measured by LC‑MS), the hypothesis that AKG acts via succinate depletion is unsupported.
• If AKG fails to improve epigenetic age metrics in TET2/3 KO mice despite normalizing HIF‑1α, yet still extends lifespan, then the link between HIF‑1α regulation and epigenetic rejuvenation is not necessary for the observed phenotype.

This framework directs a clear set of biochemical, genetic, and physiological experiments that can distinguish metabolic repair from hormetic signaling and clarify AKG’s role in aging.